SupplementScore.org

Curcumin-induced liver injury: the DILIN case series and what to watch for

6 min read · By the · Updated · How we research
Bottom Line

Curcumin was long assumed to protect the liver, which holds for dietary turmeric but is misleading for the bioavailability-enhanced supplements now on shelves. An Italian outbreak (27 cases of acute hepatitis, one transplant) and the US DILIN registry (10 cases, most after 2018) have tied acute, mostly hepatocellular liver injury to phytosome, micellar, and piperine-paired products — not to culinary turmeric, which is too poorly absorbed to reach toxic exposure. The risk appears partly immunogenetic: the HLA-B*35:01 allele linked to green-tea-extract hepatotoxicity was present in about 70% of curcumin cases, so a prior polyphenol-induced hepatitis raises the stakes. Injury usually appears 1–3 months in with jaundice, dark urine, and fatigue, so it is reasonable to take enhanced products with food, consider baseline and 8-week ALT testing, avoid stacking other hepatotoxins, and stop immediately if those symptoms develop.

The past five years have produced a small but real case series of acute drug-induced liver injury attributed to high-bioavailability curcumin formulations, and the DILIN registry has now characterised who is at risk and what to watch for.

The Italian outbreak that opened the question

In 2018-2019, the Italian Ministry of Health identified 27 cases of acute hepatitis associated with concentrated curcumin supplements, several of which required hospitalisation and one resulting in liver transplantation. A subsequent case-series publication characterised the products as primarily phytosome or lecithin-formulated curcumin marketed for joint and inflammatory support.1 The cases prompted withdrawal of several products and the Italian National Institute of Health issued a 2019 advisory on bioavailability-enhanced curcumin.

The DILIN data

The US Drug Induced Liver Injury Network identified 10 cases of curcumin-induced liver injury in its prospective registry between 2004 and 2022, with the majority occurring after 2018, paralleling the rise of bioavailability-enhanced formulations.2 The clinical pattern was predominantly hepatocellular injury with elevated transaminases (median ALT ~1,300 U/L), latency of 30–90 days from product initiation, and a 60% rate of jaundice. All but one of the DILIN cases involved formulations marketed as "absorption-enhanced" — phytosome, micellar, or piperine-coadministered curcumin.

The HLA-B*35:01 connection

This suggests a shared immunogenetic susceptibility for polyphenol-induced liver injury rather than two unrelated pharmacokinetic problems. The implication is practical: a patient with prior hepatitis attributed to one polyphenol supplement is at materially elevated risk for a similar reaction to another.

The piperine and absorption-enhancer interaction

Native turmeric powder consumed as a culinary ingredient does not produce hepatic exposure sufficient to cause liver injury — the molecule is too poorly absorbed. The cases overwhelmingly involve formulations specifically designed to circumvent that low absorption: phytosome (Meriva), liposomal, micellar, and piperine-coadministered products. Piperine also inhibits hepatic glucuronidation, prolonging exposure to potentially toxic intermediates.

Clinical recognition

Curcumin-induced liver injury typically presents 1–3 months after starting a bioavailability-enhanced product, with malaise, dark urine, jaundice, and pruritus. Liver enzymes show a hepatocellular pattern with ALT often 5–50× upper limit of normal. The 2023 European Association for the Study of the Liver guidance on drug-induced liver injury specifically lists curcumin among the recognised botanical hepatotoxins.3 Resolution typically follows product discontinuation within 4–12 weeks but several reported cases have required transplant evaluation.

The benefit-risk reading

The reasonable 2026 position is that curcumin is a useful supplement at risk-adjusted doses but not a benign one. Anyone using a bioavailability-enhanced formulation should: take it with food (which slows absorption modestly), avoid coadministration with other potential hepatotoxins, consider baseline ALT testing before starting and after 8 weeks if continuing, and stop immediately and seek medical evaluation if jaundice, dark urine, or persistent fatigue develop.

Sources

  1. Lombardi N, Crescioli G, Maggini V, et al. "Acute liver injury following turmeric use in Tuscany: an analysis of the Italian phytovigilance database and systematic review of case reports." Br J Clin Pharmacol, 2021;87(3):741-753. PMID: 32656820. DOI: 10.1111/bcp.14460
  2. Halegoua-DeMarzio D, Navarro V, Ahmad J, et al. "Liver injury associated with turmeric — a growing problem: ten cases from the drug-induced liver injury network." Am J Med, 2023;136(2):200-206. PMID: 36252717. DOI: 10.1016/j.amjmed.2022.09.026
  3. European Association for the Study of the Liver. "EASL Clinical Practice Guidelines: drug-induced liver injury." J Hepatol, 2019;70(6):1222-1261. PMID: 30926241. DOI: 10.1016/j.jhep.2019.02.014